on 26 Jul 2021
Last Applicant/ Owned by
ITM Isotope Technologies Munich SE
Lichtenbergstr. 1, 85748
Garching, ,
Serial Number
UK00003673555 filed on 26th Jul 2021
Registration Number
UK00003673555 registered on
3rd Dec 2021
Correspondent Information
Withers & Rogers LLP
2 London Bridge
London,
SE1 9RA
Radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, In particular radiopharmaceutical preparations for endo-radionuclide therapy, brachytherapy and radiopharmaceutical preparations for positron emission tomography [PET] or single photon emission tomography [SPECT], target radionuclide and peptide receptor radionuclide therapy [PRRT]; Theranostics in the field of precision oncology; Radiopharmaceutical products, Namely precursor compositions containing lutetium [precursors]; Solutions relating to radiolabelling; Radiopharmaceutical preparations for use in oncology, Namely radiopharmaceuticals containing radioisotopes, including lutetium-177, actinium-225, yttrium-90 for the treatment of, and radioisotopes including gallium-68 or fluor-18 for the diagnosis of tumours; Target radiopharmaceuticals containing a target molecule, including peptides or antibodies, independent of the indication and a medical radioactive isotope radiopharmaceutical containing gallium and complexes thereof, gallium-68 DOTATOC; 177 Lu-edotreotide preparations for targeted radionuclide therapy in patients with neuroendocrine tumours of gastroenteritic or pancreatic origin [GEP-NET]; Radiopharmaceuticals for use in GEP-NET therapy, osteosarcomas, bone metastases, prostrate cancer, breast cancer, brain cancer, ovarian cancer; Radiopharmaceuticals containing radioisotopes with shirt half-lives, including gallium-68 or fluor-18 for diagnostic applications; Radiopharmaceuticals for use with highly sensitive molecular imaging technology including PET [positron emission tomography] or SPECT [single photon emission tomography], for the creation of images of organs and lesions and for early diagnosis of diseases; Radiopharmaceuticals containing medical radioisotopes with long half-lives, including lutetium-177, actinium-225 or yttrium-90 for the treatment of tumorous diseases.
Medical instruments, apparatus and containers for the application of radiopharmaceutical preparations and radiodiagnostic preparations; Control, regulation and measuring apparatus being parts of medical instruments, apparatus and containers included in this class, in particular apparatus for therapy and diagnostics with a radiotherapeutic or radiodiagnostic substance; Radionuclide generators for radiopharmaceutical purposes.
Conducting of clinical studies in all stages and with a variety of indications, in particular in oncology; Conducting of clinical studies in phase III with the target radiopharmaceutical 177 Lu-edotreotide in patients with neuroendocrine tumours of gastroenteritic or pancreatic origin [GEP-NET].
Medical services, In particular services in the field of radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology and nuclear medicine and brachytherapy including intercavitary, interstitial and intravascular brachytherapies, radionuclide labelling, PET and SPECT scanning and target radionuclide therapy, peptide receptor radionuclide therapy [PRRT], personal nuclear medicine and precision oncology.
UK00003673555
Figurative
Individual